and Retreatment Period. ClinicalTrials.gov Identifier: NCT06108544. Updated November 11, 2025. Accessed December 2025.https://clinicaltrials.gov/study/NCT06108544.

Muromoto R, Oritani K, Matsuda T. Current Understanding of the Role of Tyrosine Kinase 2 Signaling in Immune Responses.World J Biol Chem. 2022;13(1):1–14. doi:10.4331/wjbc.v13.i1.1.

Danese S, Peyrin-Biroulet L. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.Inflamm Bowel Dis.2021;27(12):2023-2030. doi: 10.1093/ibd/izab135.

Rusiñol L, Puig L. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.Int J Mol Sci. 2023;24(4):3391. Published 2023 Feb 8. doi:10.3390/ijms24043391.

Krueger JG, McInnes IB, Blauvelt A. Tyrosine Kinase 2 and Janus KinaseSignal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis.J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869.

=*=*=*=*=*=
当前为第19/20页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页